Collaboration with Nigerian Afrobeats Legend to Bring a Suite of High-Tech Vapes and One-of-a-Kind Product Flavors to Consumers

LOS ANGELES, Dec. 14, 2023 /PRNewswire/ —  Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a leader in the development and commercialization of vaping technology and precision dosing, announced that Aspire North America, LLC (“Aspire”), one of Ispire’s operating subsidiaries, has entered a five-year exclusive global manufacturing and distribution agreement (the “Agreement”) with a prominent lifestyle brand, BrkFst, a brand co-created by GRAMMY-Award winner Burna Boy and his inner circle of  young entrepreneurs last year, and it has garnered significant community backing.

Under the Agreement, Ispire has secured the exclusive rights to distribute and commercialize BrkFst branded high-quality vapor products, including a suite of unique varieties and new flavors. Ispire is a leader in vaping technology, research and development, design and innovation that is forging the worldwide industry standard for vaporized products. The Company offers a complete line of pod-systems, cartridges, disposables, batteries and other vaping products.

“As the pioneer of the ‘cloud chasing’ movement with more than 500 patents owned or exclusively licensed around the globe, our collaboration with BrkFst brings consumers award-winning vaping technologies and one-of-a-kind products that they won’t be able to get anywhere else in the world,” said Ispire Technology Co-Chief Executive Officer Michael Wang . “Our leading-edge products are the result of many years of intense research and development and follow the highest quality standards and latest compliance rules. We look forward to partnering with more like-minded individuals and companies like BrkFst and bringing consumers more of the products they want.”

The products will be launched in Nigeria, Ghana and South Africa this month with full European Union and United Kingdom launches expected in Q2 2024.

About BrkFst
BrkFst is more than a lifestyle brand; it’s a force that’s reshaping the intersection of fashion and influencing the culture. We hope to bring that to the new BRKFST vapes. Our commitment is to redefine the narrative, creating a space that goes beyond trends and exclusivity, embracing an inclusive environment that welcomes all.

About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 500 patents received or filed globally. Ispire’s tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company’s cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on  Instagram, LinkedIn, Facebook, Twitter and YouTube.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: the Company’s ability to collect its accounts receivable in a timely manner, the Company’s business strategies, the ability of the Company to market to the Ispire ONE, Ispire ONE’s success if meeting its goals, the ability of its customers to derive the anticipated benefits of the Ispire ONE and the success of their products on the markets; the Ispire ONE proving to be safe, and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2023 and any subsequent filings which Ispire makes with the U.S. Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the press release relate only to events or information as of the date on which the statements are made in the press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

Investor Relations and Media Contacts:

For more information, kindly contact:

Investor Relations Contact:
Sherry Zheng
718-213-7386
ir@ispiretechnology.com

Media Contact:
Ellen Mellody
570-209-2947
ispire@kcsa.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/aspire-north-america-llc-enters-five-year-exclusive-global-manufacturing-and-distribution-agreement-with-lifestyle-brand-brkfst-302014528.html

SOURCE Ispire Technology Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

First Collaboration with Global Rapper & Cannabis Icon Snoop Dogg and Dogg Lbs

LOS ANGELES, Nov. 9, 2023 /PRNewswire/ — Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a leader in the development and commercialization of vaping technology and precision dosing, announced that Aspire North America, LLC (“Aspire”), one of Ispire’s operating subsidiaries, has entered a five-year exclusive manufacturing and global distribution agreements (the “Agreement”) with Hempacco Co., Inc. and its affiliate (“Hempacco”), a manufacturer of hemp-based alternatives, cannabinoid smokables and rolling papers and subsidiary of Green Globe International Inc. (OTC: GGII).

Under the Agreement, Aspire has agreed to supply, distribute and commercialize Hempacco’s branded cannabinoid and nicotine vapor products, namely Dogg Lbs by Snoop Dogg, a rap legend and entertainment icon. Ispire is a leader in vaping technology, research and development, design and innovation that is forging the worldwide industry standard for vaporized products. The Company offers a complete line of cartridges, disposables, batteries and dabbing products.

“By leveraging Ispire’s expertise in bringing to market cutting-edge vaping and precision dosing technologies and devices and Hempacco’s leadership position in the herb and hemp-based alternatives sector, we plan to set new standards for the cannabis industry and its consumers,” said Ispire Technology Co-Chief Executive Officer Michael Wang. “I don’t know many people who don’t recognize or appreciate the global impact that Snoop Dogg has had – both as an artist and cultural icon – on the cannabis industry. With our innovation, commitment to quality and collaboration, we look forward to expanding the reach of Dogg Lbs while driving sales and visibility across the cannabis sector.”

As part of the Company’s international expansion strategy and pursuant to the Agreement, Ispire will exclusively distribute vaping products worldwide for Hempacco, using the Company’s existing vapor ecosystem, which currently generates more than $100 million in revenue each year. Ispire will also oversee manufacturing and quality control of Hempacco’s vaping hardware.

“Earlier this year, we launched Dogg Lbs hemp-derived CBD and Delta-9 infused gummies, which were well received,” said Hempacco Chief Executive Officer Sandro Piancone. “Our collaboration with Ispire will help Dogg Lbs expand its reach and presence in the e-cigarette and vape market, which was valued at USD 22.45 Billion in 2022 and is projected to reach USD 190.00 Billion by 2030, according to Verified Market Research.”

About Hempacco

Hempacco Co., Inc. is Disrupting Tobacco with its herb and hemp-based alternatives to nicotine cigarettes and manufacturing and marketing of herb, spice and cannabinoid smokables and rolling papers. Hempacco’s operating segments include: manufacturing of smokables, hemp rolling papers and cannabinoid sticks; smokable technology development; the Real Stuff brand of functional smokables and rolling papers; Cheech and Chong Hemp Cigarettes and Hemp Hop Smokeables with Rick Ross; as well as a joint venture with Snoop Dogg and his line of hemp-derived product line Dogg Lbs. To learn more, visit www.hempacco.com.

About Ispire Technology Inc.

Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 200 patents received or filed globally. Ispire’s tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company’s cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on  Instagram, LinkedIn, Facebook, Twitter and YouTube.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: the Company’s ability to collect its accounts receivable in a timely manner, the Company’s business strategies, the ability of the Company to market to the Ispire ONE, Ispire ONE’s success if meeting its goals, the ability of its customers to derive the anticipated benefits of the Ispire ONE and the success of their products on the markets; the Ispire ONE proving to be safe, and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2023 and any subsequent filings which Ispire makes with the U.S. Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the press release relate only to events or information as of the date on which the statements are made in the press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

Contact:

 For more information, kindly contact:

 Investor Relations

 Sherry Zheng

 718.213.7386

 ir@ispiretechnology.com

SOURCE Ispire Technology Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, BC, TORONTO and LONDON, May 23, 2023 /PRNewswire/ – BZAM Ltd. (the “Company” or “BZAM“) (CSE: BZAM) (US-OTC: BZAMF), is pleased to announce that its subsidiary, The Green Organic Dutchman Ltd. (collectively the “Company”) has entered into a strategic distribution agreement with 4C LABS Ltd. (“4C LABS”), a London, UK based import & distribution company focused on the medical cannabis space. The Company and 4C LABS expect to commercialize medical cannabis products under The Green Organic Dutchman brand in the UK beginning in Q4 2023.

Pursuant to the agreement, signed on April 29, 2023, the Company will supply 4C LABS with approximately 600KG of flower annually for the next two years.

The Company is a premier, certified organic grower of medical cannabis in living soil. The Company recently received EU GMP certification for its greenhouse facility located in Ancaster, Ontario, Canada. This certification permits the Company to export certain medical cannabis products to numerous global markets, including the UK.

4C LABS believes that there is strong demand for quality, organic Canadian cannabis products in the UK’s burgeoning medical cannabis market. The team at 4C LABS expects the market to expand over the next five years, mirroring previously legalized medical markets elsewhere, and expects this new agreement will enable them to establish a dominant position in the UK medical cannabis market.

Matt Milich, BZAM’s CEO, stated: “We are proud to announce this agreement with 4C LABS to bring our exceptional product to the UK market. Executing on our recent EU GMP Certification is a key priority and we are excited to be able to partner with local experts like 4C LABS.”

Greg Dobbin, 4C LABS CEO, stated: “We are extremely pleased to be able to offer The Green Organic Dutchman products to our UK patients. BZAM is a world class company which operates a truly innovative facility where Canada’s best growers and unique genetics come together. From feeding certain plants maple syrup to creating community gardens at their grow facility, the BZAM team takes medical cannabis to the next level.”

About BZAM Ltd.

BZAM Ltd. (CSE: BZAM) (OTC: BZAMF) is a leading Canadian cannabis producer with a focus on branded consumer goods, innovation, quality, consistency, integrity, sustainability and transparency. The BZAM family includes core brands BZAM, TGOD, ness, Highly Dutch Organic, TABLE TOP, and partner brands Dunn Cannabis, FRESH and Wyld. BZAM operates facilities in BC, Alberta, Ontario and Quebec, as well as retail stores in Winnipeg, Manitoba and Regina, Saskatchewan.

BZAM’s Common Shares and certain warrants issued under the indentures dated June 12, 2020, October 23, 2020, and December 10, 2020, currently trade on the Canadian Securities Exchange (the “CSE”) under the symbol “BZAM”. BZAM’s Common Shares trade in the U.S. on the OTCQX under the symbol “BZAMF”. For more information, please visit www.bzam.com

About 4C LABS Ltd.

4C LABS Ltd. is a privately held UK medical cannabis company focusing on providing patients with world class medical cannabis products at an affordable price. 4C LABS has import and distribution licenses in the UK and a wide network of pharmacies in the UK & Channel Islands. 4C LABS carries a full product line of medical cannabis from a selected network of trusted international cultivation partners. For more information, please visit www.4clabs.co

Cautionary Statements

This news release includes statements containing certain “forward–looking information” within the meaning of applicable securities law (“forward–looking statements”). Forward looking statements in this release include, but are not limited to, statements about future production quantity and timing, statements about the offering of any particular products by the Company and statements regarding the future performance of the Company, statements about funding availability, statements about growth and delivery of products, and statements about the level of demand for BZAM’s products, statements relating to the creation and timing of any revenue in the UK, and statements about the future size of any international markets. Forward–looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “should”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward–looking statements throughout this news release, such as assumptions that the Company’s financial trajectory will continue, the Company not having any issues with regulators, cultivation patterns at the Company’s facilities continuing and there not being significant disruptions in cultivation such as disease or shortages in resources, the Company being insulated from supply chain issues and inflation affecting the global economy, the Company being able to access the capital markets and existing lenders for necessary funding, when necessary, demand for the Company’s products continuing as expected and based on past trends. Forward–looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties (including market conditions) and other factors that could cause actual events or results to differ materially from those projected in the forward–looking statements, including those risk factors described in Management’s Discussion and Analysis and the Company’s most recent Annual Information Form filed with Canadian securities regulators and available on the Company’s issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward–looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the CSE nor the CSE’s Regulation Services Provider (as that term is defined in the policies of CSE) accept responsibility for the adequacy or accuracy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

MIAMI & TORONTO, March 14, 2022–(BUSINESS WIRE)–Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, announced today that it has signed a distribution agreement with Israel-based, DNO Group, to distribute the Mind Naturals brand in the Hong Kong region. DNO Group is a leading distributor of global independent brands and has over 50,000 points of sale throughout Asia in addition to its broader global reach.

Through this agreement, Flora will work with DNO to identify growth opportunities and bring the Mind Naturals brand to market in new territories using an omnichannel approach including brick and mortar retail, e-commerce, and other wholesale markets. The initial focus will be on Hong Kong and is expected to be followed by a second phase expanding to India and Israel.

“We are excited to see the continued expansion of Mind Naturals into new international markets, especially those with a high demand for skincare products,” commented Flora Growth CEO, Luis Merchan. “With quality ingredients and a thoughtful customer experience, Mind offers something different in this competitive space. We look forward to working with DNO to bring this unique offering to key markets around the world.”

This announcement is one of a series of new agreements signed with international distributors. Earlier this year, Flora announced Mind Naturals launch through Walmart.com and Coppel, a nationwide department store in Mexico. The launch includes 12 products initially offered on e-commerce with subsequent plans to sell in brick and mortar retail locations. Mind Naturals has also completed initial exports to Spain.

Flora’s Mind Naturals emphasizes the idea that beauty starts in the mind. It is an inclusive brand that uses premium CBD and quality, clean ingredients to develop better-for-you skincare in more sustainable packaging than traditional brands. They were named a trendsetting brand at CosmoProf North America in 2021 for their innovation in sustainable packaging and in December were a top 12 finalist in Glosswire’s Global Pitch Competition, which includes beauty brands from across the globe.

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that is designed to deliver one of the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. Visit www.floragrowth.com or follow @floragrowthcorp on social [media] for more information.

Cautionary Statement Concerning Forward-Looking Statements

This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: the size of markets for cannabis and cannabis products; the collaboration with third parties; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, or the forward-looking events discussed in this document and other statements made from time to time by us or our representatives not occurring, except as may be required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005305/en/

Contacts

Investor Relations:
Evan Veryard
[email protected]

Public Relations:
Cassandra Dowell
+1 (858) 264-6600
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Deal Includes Exclusive Distribution Rights for CLIPPER^® Lighters in the U.S. and Canada

LOUISVILLE, Ky., February 22, 2022–(BUSINESS WIRE)–Turning Point Brands, Inc. (“TPB” or “the Company”) (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, including alternative smoking accessories and consumables with active ingredients, announced today that it has entered into an agreement with Flamagas, a renowned lighter manufacturer, for exclusive distribution of CLIPPER^® lighters in the United States and Canada.

CLIPPER is the number one reusable lighter in the world and the number two overall world lighter brand. CLIPPER is currently available in several leading retail chains with growing presence in additional retail outlets, dispensaries, smoke shops and headshops. Its products are grounded in over 60 years of manufacturing experience and continuous investment in producing the safest premium lighters made by Flamagas. Through its unique, iconic cylindrical shape and trendy collections, CLIPPER^® has become the lighter of choice for its loyal global consumer base as well as the preferred partner for leading brands and retailers in the roll-your-own cannabis and tobacco markets.

“Given Flamagas’ global reach and renowned product portfolio, this partnership represents a tremendous opportunity to expand CLIPPER’s reach in the United States and Canada,” said Frank Vignone, Senior Vice President of Sales and Marketing at Turning Point Brands. “CLIPPER and Zig-Zag create a powerful combination of iconic premium brands in the roll-your-own market perfectly suited to leverage Turning Point Brands’ distribution infrastructure touching over 210,000 retail outlets in North America.”

“Turning Point Brands is the ideal partner for us to expand CLIPPER’s already strong global following,” said Jordi Marce, Chief Business Officer at Clipper. “CLIPPER has a proven marketing model that has led to success with our partners in other regions, including establishing the leading position in major markets in Europe, Middle East and other worldwide areas. We are confident that we can implement a similar strategy with Turning Point Brands to extend access to our traditional and utility lighters to more consumers.”

For more information about becoming a wholesale or retail customer of CLIPPER lighters, please e-mail [email protected].

About Turning Point Brands, Inc.

Turning Point Brands (NYSE: TPB) is a manufacturer, marketer and distributor of branded consumer products including alternative smoking accessories and consumables with active ingredients through its iconic Zig-Zag® and Stoker’s® brands, and its emerging brands within the NewGen segment. TPB’s products are available in more than 210,000 retail outlets in North America, and on sites such as www.zigzag.com, www.nu-x.com and www.solacevapor.com. For the latest news and information about TPB and its brands, please visit www.turningpointbrands.com.

About Flamagas

Headquartered in Barcelona, Spain, FLAMAGAS has been a world leader in the lighter industry for over six decades. Its CLIPPER^® lighter is the number one reusable lighter and has become an iconic fashion lighter. For more information about CLIPPER^® lighters, please visit www.clipperofficial.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005195/en/

Contacts

Media Contacts
Turning Point Brands, Inc.:
Raquel Cona
KCSA Strategic Communications
212.896.1204
[email protected]

Investor Contacts
Turning Point Brands, Inc.:
Louie Reformina, Senior Vice President, CFO
Turning Point Brands, Inc.
502.774.9238
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Announcement of distribution agreement coincides with appearance of both
companies at Arab Health 2022, the largest medical equipment exhibition in the Middle East

VANCOUVER, BC, Jan. 27, 2022 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) today announced that it has signed a distribution agreement with Dubai-based medical technology company Emitac Healthcare Solutions (“Emitac”). Under the terms of the agreement, Emitac has become an official distributor of CognICA, Cognetivity’s medical device product, in the Middle East region.

Emitac is a leading healthcare innovator and solutions provider in the Middle East, with over 45 years of experience in the healthcare industry. It boasts an impressive array of public- and private-sector organisations among its customers and clients, from Dubai Healthcare City and the United Arab Emirates Ministry of Health & Prevention to Cleveland Clinic, Samsung Ultrasound Systems and Philips Healthcare.

CognICA is Cognetivity’s flagship medical device product. It is a cutting-edge, computerized test of cognitive function that offers numerous advantages over traditional pen-and-paper examinations, such as its short testing duration and high classification accuracy, coupled with the absence of a learning effect or any cultural or educational bias.

CognICA is FDA-registered and CE-marked, and has already been commercially deployed across three continents, including within the UK’s National Health Service (NHS) and in the state-of-the-art Clemenceau Medical Center in Dubai. The new agreement grants Cognetivity access to Emitac’s wealth of experience and connections in the Middle East, as well as the full range of its customer support services, in order to bolster CognICA’s already-impressive commercial rollout in the region.

News of the partnership coincides with the appearance of both companies at Arab Health 2022. Taking place in Dubai from 24 to 27 January, Arab Health is the largest medical equipment exhibition in the Middle East, with exhibitors from over 60 countries participating and more than 56,000 healthcare professionals due to attend.

Cognetivity’s attendance at Arab Health and the burgeoning commercial rollout of CognICA across the Middle East come at a salient moment for the region. According to a study published this year in The Lancet Public Health, the UAE and other Gulf countries will experience the highest increases worldwide in the number of people living with dementia by 2050. This represents a major impending healthcare challenge, which cutting-edge technology such as Cognetivity’s will play a vital part in tackling.

Dr Sina Habibi, CEO of Cognetivity, said: “We’re delighted to have established this partnership with Emitac Healthcare Solutions. As its list of existing customers and clients shows, Emitac is a hugely-respected name in the region, bringing the experience and the manpower required to service our clientele and reassure customers of our commitment in this market.”

“Dementia poses a serious and widespread threat to the ageing population of the Middle East,” he added. “In order to stop dementia from turning into a healthcare crisis, we need to be bold and act fast. I am confident that this new agreement is the best way to accelerate our ongoing commercial rollout in the region and thoroughly excited about the positive impact it will have on patients’ lives.”

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.

ON BEHALF OF THE BOARD
“Sina Habibi”
Sina Habibi
Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS:

Certain statements included in this news release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “assume” “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Cognetivity Neurosciences Ltd

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The partnership will focus on the licensing, supply, and expected commercialization of Avicanna’s cannabinoid-based drug candidate Trunerox, in Argentina in the second half 2022

TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has entered into a partnership with an established Argentine pharmaceutical company to register and commercialize Avicanna’s proprietary cannabinoid-based pharmaceutical preparations through the licensing of its intellectual property and supply of its active pharmaceutical ingredients (“API”).

Through the partnership Avicanna will provide a non-exclusive license of the Company’s intellectual property related to its proprietary 10% cannabidiol (“CBD”) pharmaceutical drug preparation. Additionally, the partner will source its pharmaceutical-grade CBD exclusively from Avicanna to manufacture the product for the registration and marketing authorization with the Argentine regulatory agency ANMAT.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Agreement Expands Product Offering to Include One of the Best Sun-Grown Branded Products on the Market

Humboldt Farms Joins Korova, Sticks, Habit and FlowerShop* as a Marquee Brand in Unrivaled Distribution

SANTA ANA, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) — Unrivaled Brands, Inc. (OTCQX:UNRV) (“Unrivaled” or the “Company”) today announced that the Company has entered into an exclusive distribution agreement with Humboldt Farms. As part of the agreement, Unrivaled will be executing all sales and distribution services of Humboldt Farms branded products throughout California.

Humboldt Farms is one of California’s leading and most trusted sources for quality cannabis. Considered a staple outdoor flower brand in California, Humboldt Farms is committed to producing the world’s best sun-grown flower and highest quality cannabis products. Humboldt Farms’ premium flower is sun-ripened and organically grown on small family farms in renowned Humboldt County.

Humboldt Farms’ hand-selected buds offer maximum potency due to the cultivation of cutting-edge strains with robust genetics. The branded flower lineup includes both large and small flower available in eighths, quarters, half-ounces and ounces. The same premium flower is used to produce high-quality pre-rolls and live-rosin infused pre-rolls available in single and four-packs. Humboldt Farms’ premium live resin grams and vape cartridges are made from the finest flower that is flash frozen after harvest and stored in violet glass to preserve the integrity, flavor and terpene profiles of each strain for an unrivaled experience.

Unrivaled President Oren Schauble stated, “Unrivaled’s California distribution strategy is to have a best-in-class offering across all key product categories. With Humboldt Farms, we can now provide buyers at our partner dispensaries with one of the best sun-grown flower options on the market — from a brand whose culture and values reflect those of the Unrivaled team. Currently a top seller at Unrivaled dispensaries Blüm, The Spot and Peoples OC, we believe Humboldt Farms has the potential to be a top provider of sun-grown flower in California overall.”

Humboldt Farms Founder and CEO Zach Rubin stated, “With their bold and creative approach to sales and their understanding of the market, we feel really confident in Unrivaled’s ability to expand our footprint into hundreds of premier dispensaries. Unrivaled shares our vision of Humboldt Farms as a leading sun-grown cannabis brand of California and we look forward to their representation.”

About Unrivaled Brands

Unrivaled Brands is a multi-state vertically integrated company focused on the cannabis sector with operations in California, Oregon, and Nevada. In California, Unrivaled Brands operates four dispensaries, a state-wide distribution network, and two cultivation facilities, and has one additional cultivation facilities and five dispensaries under development. In Oregon, we operate a state-wide distribution network. In Nevada, by way of a joint venture, Unrivaled Brands operates a cultivation and manufacturing facility. Among other brands, Unrivaled Brands is home to Korova, the market leader in high potency products across multiple product categories, currently available in California, Oregon, Arizona, and Oklahoma, as well as Sticks and Cabana. For more info, please visit: unrivaledbrands.com.

Cautionary Language Concerning Forward-Looking Statements

Certain statements contained in this communication regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Unrivaled undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors.

New factors emerge from time-to-time and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks, as well as additional risks and uncertainties we face, are identified and more fully discussed in the “Risk Factors” section of Unrivaled’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to Unrivaled as of the date of this release. Unrivaled undertakes no obligation to update such forward-looking statements to reflect events or circumstances after the date of this release.

Contact
Jason Assad
LR Advisors LLC.
[email protected]
678-570-6791

For media inquiries:
Nic Johnson
Russo Partners
[email protected]
303-482-6405

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

TORONTO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness ” or the “ Company ”) (CSE: SILO) (OTCQB: SILFF) (FRA: 3K70), a leading global psychedelics company, today announced a $3 million national distribution agreement with Texas-based distribution and advertising company One Light Enterprises LLC. (“ One Light ”) for Silo Wellness’ portfolio of Marley One branded mushroom products across 47 U.S. states (the “ Distribution Agreement ”).

Today’s announcement comes on the heels of Silo Wellness’ U.K. distribution agreement with LocoSoco Group PLC, announced earlier this month. Together with the Distribution Agreement, Silo Wellness has cemented strong routes to market in both the U.S. and the U.K. for its Marley One global mushroom brand, created in collaboration with the family of legendary musician Bob Marley.

“We have seen tremendous consumer interest in the Marley One brand, and we are pleased to announce a distribution partner for the all-important U.S. market,” said Douglas K. Gordon, Chief Executive Officer, Silo Wellness. “One Light is a respected and like-minded partner who shares our vision for Marley One and our commitment to delivering best-in-class consumer experiences and products.”

One Light will distribute the full line of Marley One mushroom products, beginning with the brand’s initial five functional mushroom tinctures, to retailers across the U.S. Silo Wellness also intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules, and cosmetics.

“We are excited to partner with Silo Wellness to bring Marley One to U.S. consumers,” said Twin Rivers Group, LLC, Managing Member of One Light. “We partner with some of the best-loved brands in the market today, and we anticipate Marley One will be well-received by consumers, particularly as they seek out natural, plant-based wellness products to enhance their everyday lives.”

According to Mordor Intelligence , the global functional mushroom market was valued at USD 25,415.12 million in 2020, and is estimated to register a CAGR of 8.44% during the forecast period of 2021-2026. Mordor Intelligence also notes that functional mushrooms are expected to have increased applicability beyond healthcare or pharmaceutical products over the long term, particularly in the food and beverage sector.

Corporate Update

On August 11, 2021, the Company entered into a loan agreement with an arm’s length third party lender (the “ Lender ”) pursuant to which the Company borrowed US$250,000 for working capital and inventory growth purposes (the “ Loan ”). Subsequently, the Company entered into a debt settlement agreement with the Lender to settle US$144,000 of the Loan in exchange for 2,500,000 Common Shares at a deemed price of C$0.072 per Common Share, representing a 20% discount to the closing price of the Common Shares on August 11, 2021 (the “ Shares for Debt ”). The remaining principal amount of the Loan remains outstanding. Completion of the Shares for Debt is subject to compliance with applicable regulations, including policies of the CSE.

The Company has agreed to issue Common Shares to two arm’s length service providers in accordance with previously agreed arrangements (the “ Shares for Services ”). Pursuant to various agreement for services, the Company intends to issue an aggregate of 5,310,000 Common Shares with 5,000,000 Common Shares issued at a deemed price of C$0.13 and 310,000 Common Shares issued at a deemed price of C$0.10. Completion of the Shares for Services is subject to compliance with applicable regulations, including policies of the CSE.

The Company also announces that Peter Holzworth, vice president of business development has resigned from his position.

For more information about Silo Wellness, please visit https://www.silowellness.com/ . To buy Marley One products, please visit https://marleyone.com/ .

ABOUT SILO WELLNESS
Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has operations in Jamaica and Oregon. Silo Wellness is a publicly-traded company on the Canadian (CSE: SILO) and Frankfurt (FRA: CK70) exchanges and trading on the OTCQB Venture Market (OTCQB: SILFF).

Silo Wellness offers a diverse and growing portfolio of functional mushroom products, psychedelic wellness retreats in Jamaica and Oregon, cultivation of psychedelic mushrooms and truffles in Jamaica, development of a brick-and-mortar smart shop in Jamaica, and intellectual property, focused initially on the commercialization of its metered-dosing psilocybin nasal spray.

In March 2021, Silo Wellness announced a multi-year licensing agreement with the family of legendary musician Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. The Marley One line of functional mushrooms is available at www.marley.one .

For more information about Silo Wellness, please visit www.silowellness.com .

For further information, please contact:

Silo Wellness Media Relations:
[email protected]

Silo Wellness Investor Relations:
(778) 383-6740
[email protected]

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements”  (collectively, “forward-looking statements”) within the meaning of the applicable Canadian  securities legislation. All statements, other than statements of historical fact, are forward-looking  statements and are based on expectations, estimates, and projections as at the date of this news  release. Any statement that involves discussions with respect to predictions, expectations, beliefs,  plans, projections, objectives, assumptions, future events or performance (often but not always  using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not  anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or  variations of such words and phrases or stating that certain actions, events or results “may” or  “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical  fact and may be forward-looking statements. In this news release, forward-looking statements  relate, among other things, to: the Distribution Agreement the distribution partnership with One Light, the Shares for Debt, the Shares for Services and the business plans of Silo Wellness. Forward-looking statements are  necessarily based upon a number of estimates and assumptions that, while considered  reasonable, are subject to known and unknown risks, uncertainties, and other factors which may  cause the actual results and future events to differ materially from those expressed or implied by  such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19.  There can be no assurance that such statements will prove to be accurate, as actual results and  future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information  contained in this news release. Silo Wellness assumes no obligation to update the forward-looking  statements of beliefs, opinions, projections, or other factors, should they change, except as  required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES  PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS  RELEASE.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.